Lucid Diagnostics logo

Lucid Diagnostics

Molecular diagnostic tests designed for the early detection of esophageal precancer.

What they do

Lucid Diagnostics manufactures a non-invasive esophageal cell collection device paired with a molecular diagnostic test. This technology allows primary care physicians and gastroenterologists to screen patients with chronic reflux for esophageal precancer, preventing progression to lethal esophageal cancer.

The record

Vertical
Imaging & Diagnostics
Sub-segment
Esophageal cancer diagnostics
Product type
Diagnostics
Stage
Public
Headquarters
New York, USA
Region
North America
Founded
2018
Total funding
$60M raised

Notable investors: PAVmed.

Also in Imaging & Diagnostics

See the Imaging & Diagnostics market map

Related on The Signal